GlassScriptPhysician profile
Melissa Mason
NPI 1770201865
$2,611.10
in general payments reported to CMS, 2019-2025
33 companies · $771 in 2025
The $771 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $82.71 · 2023: $602 · 2024: $1,155 · 2025: $771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,528.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $647.82 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $356.00 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $186.26 | 2023-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $166.12 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $158.64 | 2022-2025 | |
| Abbvie INC. | $136.16 | 2023-2025 | |
| Dexcom, INC. | $86.80 | 2023-2025 | Dexcom G6 Transmitter |
| Aimmune Therapeutics, INC. | $78.73 | 2024-2025 | Zenpep |
| Glaxosmithkline, LLC. | $70.93 | 2024-2025 | Trelegy Ellipta, Nucala |
| Merck Sharp & Dohme LLC | $61.07 | 2023 | Delstrigo, Dificid, Gardasil 9 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.76 | 2023-2025 | Xifaxan, Relistor |
| Astellas Pharma US INC | $58.58 | 2024 | Veozah |
| Pfizer INC. | $57.65 | 2023-2025 | |
| Incyte Corporation | $56.28 | 2022-2023 | Jakafi |
| Madrigal Pharmaceuticals | $41.00 | 2025 | Rezdiffra |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $40.28 | 2023 | Gvoke Hypopen |
| Shield Therapeutics INC | $34.38 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.58 | 2023 | Iclusig |
| Regeneron Healthcare Solutions, INC. | $29.44 | 2022 | |
| Puma Biotechnology, INC. | $24.55 | 2023 | |
| Krystal Biotech INC | $24.36 | 2024 | Vyjuvek |
| Janssen Biotech, INC. | $21.99 | 2023 | Imbruvica |
| Sk Life Science, INC. | $20.86 | 2024 | |
| Corcept Therapeutics | $19.93 | 2024 | Korlym |
| Genentech USA, INC. | $19.90 | 2025 | Ocrevus Zunovo |
| Viatris Specialty LLC | $19.60 | 2025 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.75 | 2024 | |
| Phadia US INC. | $15.64 | 2025 | Immunocap |
| Seagen INC. | $15.48 | 2023 | Adcetris |
| Sobi, INC | $15.11 | 2023 | |
| Pharming Healthcare, INC. | $14.66 | 2023 | Ruconest |
| Exact Sciences Corporation | $13.55 | 2024 | Cologuard Collection Kit |
| Cequr Corporation | $13.24 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Mason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.